RxDoctor Payments Data

Christopher Collins, MD

Family Medicine · Lubbock, TXNPI 1932390960

Payments from drug & device makers

$684in general payments, 2019–2025

Across 28 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$253
  • Amgen$192
  • Dexcom, Inc.$145
  • Globus Medical$26
  • Genentech USA, Inc.$21
  • AbbVie$16
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$99,391
Medicare patients
282
Services billed
2,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$61,279
OzempicSemaglutide23$29,709
JanuviaSitagliptin Phosphate20$19,962
EliquisApixaban22$18,687
TrulicityDulaglutide11$9,925
FarxigaDapagliflozin Propanediol11$8,313
Pregabalin13$3,153
SymbicortBudesonide/Formoterol Fumarate11$3,063
Albuterol Sulfate HfaAlbuterol Sulfate95$2,194
Atorvastatin Calcium256$2,156
LantusInsulin Glargine,hum.Rec.Anlog12$2,144
Montelukast Sodium128$1,500
Gabapentin103$1,439
Levothyroxine Sodium158$1,427
Omeprazole112$1,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$253$71,20561 claims
Novo NordiskOzempic$15$29,70923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →